Percheron Therapeutics lays out expected timeline for avicursen trial data
Percheron Therapeutics (ASX:PER) expects to deliver topline data from its Duchenne muscular…
Percheron Therapeutics Limited (ASX:PER)
About Percheron Therapeutics Limited
Key Information
PER In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 18/12/2024 | Price Sensitive PS Topline Six-Month Results From Phase IIb Study of Avicursen | 108.97KB | 49K |
| 16/12/2024 | Price Sensitive PS Trading Halt | 188.35KB | 42K |
| 03/12/2024 | Reorganisation of US Quoted Securities | 97.41KB | 1.4K |
| 02/12/2024 | Price Sensitive PS Clinical Trial Update | 103.19KB | 94K |
| 02/12/2024 | Resignation of Joint Company Secretary | 93.65KB | 1.7K |
| 29/11/2024 | Notification regarding unquoted securities - PER | 23.67KB | 434 |
| 28/11/2024 | Change of Director's Interest Notice - Dr James Garner | 202.01KB | 2.6K |
| 27/11/2024 | Notice under S708A | 201.63KB | 3.5K |